These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 34232944)

  • 1. Analysis of clinical factors associated with survival in patients with soft-tissue sarcoma receiving trabectedin.
    Simetić L; Blažičević K; Ladenhauser T; Golčić M; Majnarić T; Herceg D
    Anticancer Drugs; 2021 Nov; 32(10):1058-1066. PubMed ID: 34232944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of trabectedin for patients with unresectable and relapsed soft-tissue sarcoma in Japan: A Japanese Musculoskeletal Oncology Group study.
    Kobayashi H; Iwata S; Wakamatsu T; Hayakawa K; Yonemoto T; Wasa J; Oka H; Ueda T; Tanaka S
    Cancer; 2020 Mar; 126(6):1253-1263. PubMed ID: 31825533
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of trabectedin in advanced soft tissue sarcoma: beyond lipo- and leiomyosarcoma.
    De Sanctis R; Marrari A; Marchetti S; Mussi C; Balzarini L; Lutman FR; Daolio P; Bastoni S; Bertuzzi AF; Quagliuolo V; Santoro A
    Drug Des Devel Ther; 2015; 9():5785-91. PubMed ID: 26604682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retrospective Analysis of Trabectedin Therapy for Soft Tissue Sarcoma.
    Kawaguchi K; Nakano K; Urasaki T; Fukuda N; Taira S; Ono M; Tomomatsu J; Nishizawa M; Ae K; Matsumoto S; Takahashi S
    In Vivo; 2019; 33(5):1609-1614. PubMed ID: 31471412
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trabectedin for the treatment of advanced metastatic soft tissue sarcoma.
    Simpson EL; Rafia R; Stevenson MD; Papaioannou D
    Health Technol Assess; 2010 May; 14 Suppl 1():63-7. PubMed ID: 20507805
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Austrian experience with trabectedin in non-selected patients with metastatic soft tissue sarcoma (STS).
    Ploner F; Lamm W; Schur S; Eisterer W; Kühr T; Lindorfer A; Tinchon C; Köstler WJ; Szkandera J; Brodowicz T
    J Cancer Res Clin Oncol; 2013 Aug; 139(8):1337-42. PubMed ID: 23666164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-World Experience of Efficacy and Safety of Trabectedin in Patients with Soft Tissue Sarcoma: A Bicentric Retrospective Analysis.
    Chaigneau L; Jary M; Nerich V; Hervieu A; Aubry S; Charon Barra C; Meynard G; Neumann F; Kalbacher E; Isambert N
    Oncology; 2022; 100(12):633-644. PubMed ID: 36283345
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predicting Trabectedin Efficacy in Soft Tissue Sarcoma: Inflammatory Biomarker Analysis.
    Imai T; Kojima Y; Shimoi T; Aiba H; Okuma HS; Saito A; Kita S; Yamamoto K; Maejima A; Nishikawa T; Sudo K; Noguchi E; Yoshida A; Matsui Y; Iwata S; Kobayashi E; Kawai A; Udagawa R; Fujiwara Y; Yonemori K
    Anticancer Res; 2024 May; 44(5):2125-2132. PubMed ID: 38677749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Danish experience with trabectedin treatment for metastatic sarcoma: Importance of hyponatremia.
    Schack LH; Mouritsen LS; Elowsson C; Krarup-Hansen A; Safwat A
    Acta Oncol; 2015 Jan; 54(1):34-40. PubMed ID: 25263179
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and tolerability of trabectedin in elderly patients with sarcoma: subgroup analysis from a phase III, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma.
    Jones RL; Demetri GD; Schuetze SM; Milhem M; Elias A; Van Tine BA; Hamm J; McCarthy S; Wang G; Parekh T; Knoblauch R; Hensley ML; Maki RG; Patel S; von Mehren M
    Ann Oncol; 2018 Sep; 29(9):1995-2002. PubMed ID: 30084934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of Trabectedin in Patients with Advanced Translocation-Related Sarcomas: Pooled Analysis of Two Phase II Studies.
    Takahashi M; Takahashi S; Araki N; Sugiura H; Ueda T; Yonemoto T; Morioka H; Hiraga H; Hiruma T; Kunisada T; Matsumine A; Shimura M; Kawai A
    Oncologist; 2017 Aug; 22(8):979-988. PubMed ID: 28526720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trabectedin in advanced soft tissue sarcoma: case series.
    Demirci U; Buyukberber S; Yetisyigit T; Dizdar O; Benekli M; Alkis N; Coskun U;
    J BUON; 2012; 17(3):591-2. PubMed ID: 23033305
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trabectedin for Advanced Soft Tissue Sarcoma: Ten Year Real-Life Perspective.
    Shamai S; Merimsky O
    Isr Med Assoc J; 2018 Oct; 20(10):599-603. PubMed ID: 30324774
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trabectedin use in soft-tissue sarcoma patients in a real-world setting: Data from an Italian national drug-access registry.
    Vincenzi B; Napolitano A; Comandone A; Sanfilippo R; Celant S; Olimpieri PP; Di Segni S; Russo P; Casali PG
    Int J Cancer; 2023 Feb; 152(4):761-768. PubMed ID: 36196483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trabectedin for metastatic soft tissue sarcoma: a retrospective single center analysis.
    Schmitt T; Keller E; Dietrich S; Wuchter P; Ho AD; Egerer G
    Mar Drugs; 2010 Oct; 8(10):2647-58. PubMed ID: 21116412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics, safety, and activity of trabectedin as first-line treatment in elderly patients who are affected by advanced sarcoma and are unfit to receive standard chemotherapy: A phase 2 study (TR1US study) from the Italian Sarcoma Group.
    Grosso F; D'Ambrosio L; Zucchetti M; Ibrahim T; Tamberi S; Matteo C; Rulli E; Comandini D; Palmerini E; Baldi GG; DeCensi A; Bergaglio M; Marra D; Marchesi E; Siri G; D'Incalci M; Grignani G
    Cancer; 2020 Nov; 126(21):4726-4734. PubMed ID: 32749681
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): an open-label, phase 1b study from the Italian Sarcoma Group.
    Grignani G; D'Ambrosio L; Pignochino Y; Palmerini E; Zucchetti M; Boccone P; Aliberti S; Stacchiotti S; Bertulli R; Piana R; Miano S; Tolomeo F; Chiabotto G; Sangiolo D; Pisacane A; Dei Tos AP; Novara L; Bartolini A; Marchesi E; D'Incalci M; Bardelli A; Picci P; Ferrari S; Aglietta M
    Lancet Oncol; 2018 Oct; 19(10):1360-1371. PubMed ID: 30217671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protocol for the 2ND-STEP study, Japan Clinical Oncology Group study JCOG1802: a randomized phase II trial of second-line treatment for advanced soft tissue sarcoma comparing trabectedin, eribulin and pazopanib.
    Endo M; Kataoka T; Fujiwara T; Tsukushi S; Takahashi M; Kobayashi E; Yamada Y; Tanaka T; Nezu Y; Hiraga H; Wasa J; Nagano A; Nakano K; Nakayama R; Hamada T; Kawano M; Torigoe T; Sakamoto A; Asanuma K; Morii T; Machida R; Sekino Y; Fukuda H; Oda Y; Ozaki T; Tanaka K
    BMC Cancer; 2023 Mar; 23(1):219. PubMed ID: 36890471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A retrospective analysis of antitumour activity with trabectedin in translocation-related sarcomas.
    Le Cesne A; Cresta S; Maki RG; Blay JY; Verweij J; Poveda A; Casali PG; Balaña C; Schöffski P; Grosso F; Lardelli P; Nieto A; Alfaro V; Demetri GD
    Eur J Cancer; 2012 Nov; 48(16):3036-44. PubMed ID: 22749255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lack of Correlation Between Liver Tests Abnormalities and Trabectedin Efficacy in the Treatment of Soft Tissue Sarcoma: a Retrospective Study.
    Vincenzi B; Stumbo L; Maltese G; Cerbone L; Spalato Ceruso M; Badalamenti G; Santini D; Tonini G; Frezza AM; De Lisi D; Silletta M
    Sci Rep; 2015 Aug; 5():12077. PubMed ID: 26235506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.